# A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

> **NCT01892345** · PHASE3 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Eculizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01892345
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-11
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01892345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01892345, "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01892345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*